Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share (CADL)

Historical Holders from Q3 2021 to Q3 2025

Symbol
CADL on Nasdaq
Type / Class
Equity / Common stock, par value $0.0001 per share
Shares outstanding
49,625,327
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
22,652,478
Holdings value
$115,539,883
% of all portfolios
0%
Number of holders
80
Number of buys
40
Number of sells
36
Average buys %
+0%
Average sells %
-0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share (CADL) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 15% +63% $30,140,299 +$11,424,732 6,318,721 +61% FMR LLC 31 Jan 2025
ACORN BIOVENTURES, L.P. 5.2% $12,412,287 2,580,517 Anders Hove 25 Jun 2025
BAKER BROS. ADVISORS LP 5% -26% $11,710,865 -$2,513,194 2,455,108 -18% Baker Bros. Advisors LP 31 Mar 2025
As of 30 Sep 2025 Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share (CADL) has 80 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 22,652,478 shares of 49,625,327 outstanding shares and own 46% of the company stock as of 30 Sep 2025.

Top 25 institutional shareholders of Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share (CADL) own 44% of the company based on 13F filings as of 30 Sep 2025

Filer Ownership Holdings Value Nb Shares Share Change %
FMR LLC 17% $41,990,263 8,233,385 -0%
ACORN CAPITAL ADVISORS, LLC 5.2% $13,160,637 2,580,517 0%
BlackRock, Inc. 4.8% $12,134,582 2,379,330 +3.4%
VANGUARD GROUP INC 4% $10,236,272 2,007,112 +12%
Portolan Capital Management, LLC 2.8% $7,059,124 1,384,142 -15%
GEODE CAPITAL MANAGEMENT, LLC 1.9% $4,734,652 928,197 +2.7%
Halter Ferguson Financial Inc. 1.4% $3,559,821 698,004 -10%
STATE STREET CORP 1.4% $3,512,707 688,766 +5.6%
Sands Capital Alternatives, LLC 0.82% $2,069,769 405,837 0%
NORTHERN TRUST CORP 0.62% $1,564,553 306,775 +6.6%
CITADEL ADVISORS LLC 0.51% $1,286,684 252,291
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.45% $1,141,487 223,821 -37%
Nuveen, LLC 0.42% $1,069,276 209,662 +127%
Tanager Wealth Management LLP 0.4% $1,010,693 198,175 +0.79%
WELLINGTON MANAGEMENT GROUP LLP 0.28% $703,229 137,888 +60%
MILLENNIUM MANAGEMENT LLC 0.28% $697,017 136,670
TWO SIGMA INVESTMENTS, LP 0.27% $694,192 136,116 -63%
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.24% $617,120 121,004 +6.4%
MARSHALL WACE, LLP 0.21% $529,621 103,847 -36%
Bank of New York Mellon Corp 0.19% $482,300 94,569 +8.9%
UBS Group AG 0.19% $479,762 94,071 +14%
COMMONWEALTH EQUITY SERVICES, LLC 0.17% $419,000 82,221 +0.76%
Kovitz Investment Group Partners, LLC 0.16% $404,512 79,316
MORGAN STANLEY 0.15% $387,300 75,941 -33%
ALLIANCEBERNSTEIN L.P. 0.14% $352,461 69,110 0%

Institutional Holders of Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share (CADL) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price Investors
2025 Q3 22,652,478 $115,539,883 -$1,871,330 $5.10 80
2025 Q2 23,037,394 $116,569,933 +$8,831,732 $5.06 78
2025 Q1 21,190,126 $119,727,231 +$12,537,012 $5.65 82
2024 Q4 17,927,985 $155,543,630 +$97,179,819 $8.68 69
2024 Q3 6,693,196 $46,384,918 +$3,072,114 $6.93 51
2024 Q2 5,961,761 $36,963,879 +$13,959,590 $6.20 47
2024 Q1 3,780,257 $5,972,529 -$231,570 $1.58 18
2023 Q4 4,027,159 $5,919,503 -$1,196,574 $1.47 20
2023 Q3 5,257,852 $4,856,205 -$147,500 $0.9200 19
2023 Q2 5,370,044 $6,766,125 -$142,742 $1.26 19
2023 Q1 5,478,268 $7,437,200 +$69,457 $1.35 20
2022 Q4 5,420,630 $9,702,154 -$1,788,493 $1.79 20
2022 Q3 6,080,809 $19,096,287 -$834,393 $3.14 22
2022 Q2 6,345,342 $20,559,000 -$1,159,385 $3.24 19
2022 Q1 6,674,026 $33,969,000 -$1,719,794 $5.08 21
2021 Q4 6,951,728 $54,359,000 +$886,775 $7.82 20
2021 Q3 4,884,338 $52,946,000 +$44,146,995 $10.84 12